Carlisle Companies Inc (CSL)

113.97
NYSE : Consumer Goods
Prev Close 113.97
Day Low/High 0.00 / 0.00
52 Wk Low/High 75.17 / 116.40
Avg Volume 354.20K
Exchange NYSE
Shares Outstanding 64.50M
Market Cap 7.37B
EPS 4.90
P/E Ratio 29.28
Div & Yield 1.40 (1.20%)

Latest News

CSL Behring Presents Positive Results From The CSL112 AEGIS-I Phase 2b Trial

CSL Behring Presents Positive Results From The CSL112 AEGIS-I Phase 2b Trial

Study Meets Co-Primary Endpoints of Hepatic and Renal Safety and Demonstrates Proof of Mechanism

AFSTYLA®, For Haemophilia A, Receives Positive Opinion From European Medicines Agency CHMP

AFSTYLA®, For Haemophilia A, Receives Positive Opinion From European Medicines Agency CHMP

-- CHMP positive opinion moves AFSTYLA one step closer to approval in the European Union

Carlisle Companies Declares Regular Quarterly Dividend

Carlisle Companies Declares Regular Quarterly Dividend

The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) has declared a regular quarterly dividend of $0.

Carlisle Companies To Present At Baird Industrial Conference In Chicago On November 8

Carlisle Companies To Present At Baird Industrial Conference In Chicago On November 8

D. Christian "Chris" Koch, President and Chief Executive Officer of Carlisle Companies Incorporated (NYSE:CSL), will be presenting at the Baird Industrial Conference at the Four Seasons Hotel in Chicago, IL at 10:00 a.

Jim Cramer's 'Mad Money' Recap: Credibility Is the Most Valuable Currency for Investors

Jim Cramer's 'Mad Money' Recap: Credibility Is the Most Valuable Currency for Investors

Jim Cramer names companies with credibility, like NXPI and AAPL, and those that don't have it, including FIT.

CSL Behring Receives 2016 Marcum Innovator Breakthrough Award For Pioneering New Advancements In The Biotech/Healthcare Field

CSL Behring Receives 2016 Marcum Innovator Breakthrough Award For Pioneering New Advancements In The Biotech/Healthcare Field

One of the world's top specialty biotherapeutics companies, CSL Behring continues to introduce innovations to address unmet medical needs or enhance current treatments.

Carlisle Reports Loss Per Share From Continuing Operations In Third Quarter Of $0.15, Including Non-Cash Impairment Charges

Carlisle Reports Loss Per Share From Continuing Operations In Third Quarter Of $0.15, Including Non-Cash Impairment Charges

Carlisle Companies Incorporated (NYSE:CSL) reported net sales of $991.

Practicing In The Cold Ocean Waters Of The San Francisco Bay, California, The Crew Of Carlisle's American Spirit Prepares For Their Trans-Atlantic Race In December, Rowing 3000 Nautical Miles From The Canary Islands To Antigua. (Photo: Business Wire)

Practicing In The Cold Ocean Waters Of The San Francisco Bay, California, The Crew Of Carlisle's American Spirit Prepares For Their Trans-Atlantic Race In December, Rowing 3000 Nautical Miles From The Canary Islands To Antigua. (Photo: Business Wire)

Carlisle Companies Incorporated's (NYSE:CSL) American Spirit is preparing to row across the Atlantic Ocean in the Atlantic Challenge, where the competitors will begin this major nautical event on December 15.

Carlisle Companies Acquires Star Aviation

Carlisle Companies Acquires Star Aviation

Carlisle Companies Incorporated (NYSE:CSL) today announced the acquisition of Star Aviation, Inc.

Japan's Ministry Of Health, Labour And Welfare (MHLW) Approves CSL Behring's IDELVION® -- The First And Only Hemophilia B Therapy With Up To 14-day Dosing Intervals

Japan's Ministry Of Health, Labour And Welfare (MHLW) Approves CSL Behring's IDELVION® -- The First And Only Hemophilia B Therapy With Up To 14-day Dosing Intervals

- IDELVION delivers high-level protection from bleeds by maintaining factor IX activity levels at an average of 20 percent in patients treated prophylactically every 7-days and an average of 12 percent every 14-days

Carlisle Companies To Announce 3rd Quarter Results On October 25, 2016

Carlisle Companies To Announce 3rd Quarter Results On October 25, 2016

Carlisle Companies Incorporated (NYSE:CSL) will release third quarter 2016 results on Tuesday, October 25, 2016 after the market closes.

Carlisle Authorizes Repurchase Of An Additional 4.1 Million Shares

Carlisle Authorizes Repurchase Of An Additional 4.1 Million Shares

The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) has authorized Carlisle to repurchase an additional 4.

Carlisle Companies Elects Jonathan Collins To Board Of Directors

Carlisle Companies Elects Jonathan Collins To Board Of Directors

Carlisle Companies Incorporated (NYSE:CSL) announced today that Jonathan Collins, Vice President and Head of eCommerce for Mylan N.

Seqirus receives FDA approval for AFLURIA® QUADRIVALENT (Influenza Vaccine) for people 18 years of age and older

Seqirus receives FDA approval for AFLURIA® QUADRIVALENT (Influenza Vaccine) for people 18 years of age and older

NOTE TO EDITORS: On July 31, 2015 the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business, previously owned by Novartis, has been integrated into CSL's influenza vaccine business and now operates as Seqirus.

Seqirus To Highlight New Data In Seasonal Influenza Prevention At Options IX For The Control Of Influenza Conference

Seqirus To Highlight New Data In Seasonal Influenza Prevention At Options IX For The Control Of Influenza Conference

NOTE TO EDITORS: On July 31, 2015 the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business, previously owned by Novartis, has been integrated into CSL's influenza vaccine business and now operates as Seqirus.

Seqirus Presents Integrated Analyses For Trivalent Adjuvanted Seasonal Influenza Vaccine For Young Children

Seqirus Presents Integrated Analyses For Trivalent Adjuvanted Seasonal Influenza Vaccine For Young Children

NOTE TO EDITORS:On July 31, 2015 the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business, previously owned by Novartis, has been integrated into CSL's influenza vaccine business and now operates as Seqirus.

Seqirus Now Shipping Its Complete Portfolio Of Seasonal Influenza Vaccines To US Market For The 2016-2017 Season

Seqirus Now Shipping Its Complete Portfolio Of Seasonal Influenza Vaccines To US Market For The 2016-2017 Season

NOTE TO EDITORS: On July 31, 2015 the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business, previously owned by Novartis, has been integrated into CSL's influenza vaccine business and now operates as Seqirus.

Seqirus Announces Shipment Of FLUAD™ (Influenza Vaccine, Adjuvanted) In The US For 2016-2017 Flu Season

Seqirus Announces Shipment Of FLUAD™ (Influenza Vaccine, Adjuvanted) In The US For 2016-2017 Flu Season

NOTE TO EDITORS: On July 31, 2015 the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business, previously owned by Novartis, has been integrated into CSL's influenza vaccine business and now operates as Seqirus.

IIROC Trading Resumption - CSL; SNS

IIROC Trading Resumption - CSL; SNS

IIROC Trading Halt - QXP; CSL; SNS

IIROC Trading Halt - QXP; CSL; SNS

Carlisle Companies Announces 17% Increase In Dividend And The 40th Consecutive Year Of Dividend Increases

Carlisle Companies Announces 17% Increase In Dividend And The 40th Consecutive Year Of Dividend Increases

The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) has declared a 17% increase in the Company's regular quarterly dividend, to $0.

CSL Behring Presents Pivotal Efficacy Data For AFSTYLA® In Adolescents And Children With Hemophilia A At The World Federation Of Hemophilia 2016 World Congress

CSL Behring Presents Pivotal Efficacy Data For AFSTYLA® In Adolescents And Children With Hemophilia A At The World Federation Of Hemophilia 2016 World Congress

-AFSTYLA prophylaxis and on-demand treatment demonstrated long-lasting hemostatic efficacy in pediatric patients with severe hemophilia A in phase III data presented

CSL Behring Presents Phase III Data For IDELVION® For Hemophilia B At The World Federation Of Hemophilia 2016 World Congress

CSL Behring Presents Phase III Data For IDELVION® For Hemophilia B At The World Federation Of Hemophilia 2016 World Congress

New analyses from global PROLONG-9FP clinical development program show:

Carlisle Reports Record Earnings Per Share From Continuing Operations Of $1.75, A 22% Increase Over The Prior Year, And Record EBIT Margin Of 17.9% In The Second Quarter 2016

Carlisle Reports Record Earnings Per Share From Continuing Operations Of $1.75, A 22% Increase Over The Prior Year, And Record EBIT Margin Of 17.9% In The Second Quarter 2016

Carlisle Companies Incorporated (NYSE:CSL) reported net sales from continuing operations of $996.

CSL Plasma Raises Over $118,000 For The Immune Deficiency Foundation

CSL Plasma Raises Over $118,000 For The Immune Deficiency Foundation

New Giving Record Set

CSL Behring To Present New Data For IDELVION® And AFSTYLA® At The World Federation Of Hemophilia 2016 World Congress

CSL Behring To Present New Data For IDELVION® And AFSTYLA® At The World Federation Of Hemophilia 2016 World Congress

Abstracts include pivotal efficacy and safety data for IDELVION for hemophilia B and AFSTYLA for hemophilia A; AFSTYLA and IDELVION demonstrate CSL Behring's promise to develop and deliver innovative treatments that help patients with serious medical conditions live full lives